Duvelisib Plus Romidepsin for Relapsed/Refractory T-Cell Lymphomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Nat. Med. 2024 Jun 17;[EPub Ahead of Print], SM Horwitz, AJ Nirmal, J Rahman, R Xu, E Drill, N Galasso, N Ganesan, T Davey, H Hancock, L Perez, C Maccaro, A Bahgat, E Marzouk, E Cathcart, A Moskowitz, A Noy, A Kumar, E Jacobsen, DC Fisher, N Mehta-Shah, YH Kim, M Khodadoust, N Kotlov, A Nikitina, O Kudryashova, V Zubareva, K Zornikova, N Shin, M Sorokina, S Degryse, E Postovalova, A Bagaev, K Hosszu, D McAvoy, JJ Boelens, W Wu, Z Ciantra, JW Appelt, C Trevisani, S Amaka, DM Weinstock, SA VardhanaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.